143 related articles for article (PubMed ID: 2908595)
1. Detection of residual disease in acute leukemia using immunological markers.
Ryan DH; van Dongen JJ
Cancer Treat Res; 1988; 38():173-207. PubMed ID: 2908595
[No Abstract] [Full Text] [Related]
2. CAMAL: a new prognostic marker for remission in acute nonlymphoblastic leukemia.
Logan PM; Whitney S; Naiman S; Levy JG
Leuk Res; 1988; 12(1):19-24. PubMed ID: 3282127
[TBL] [Abstract][Full Text] [Related]
3. Double marker analysis for terminal deoxynucleotidyl transferase and myeloid antigens in acute nonlymphocytic leukemia patients and healthy subjects.
Adriaansen HJ; Hooijkaas H; Kappers-Klunne MC; Hählen K; van't Veer MB; van Dongen JJ
Haematol Blood Transfus; 1990; 33():41-9. PubMed ID: 2323649
[No Abstract] [Full Text] [Related]
4. Autologous bone marrow transplantation in acute leukemia and lymphoma following ex vivo treatment with monoclonal antibodies and complement.
Freedman AS; Takvorian T; Nadler LM; Anderson KC; Sallan SE; Ritz J
Cancer Treat Res; 1988; 38():265-83. PubMed ID: 2908599
[No Abstract] [Full Text] [Related]
5. The use of monoclonal antibodies and immune markers in the diagnosis, prognosis, and therapy of acute leukemia.
Neame PB; Soamboonsrup P; Quigley JG; Pewarchuck W
Transfus Med Rev; 1994 Jan; 8(1):59-75. PubMed ID: 8136608
[No Abstract] [Full Text] [Related]
6. [Minimal residual disease].
Francia di Celle P; Foà R
Haematologica; 1991 Jun; 76 Suppl 3():303-10. PubMed ID: 1752527
[No Abstract] [Full Text] [Related]
7. Usefulness of quantitative assessment of the WT1 gene transcript as a marker for minimal residual disease detection.
Cilloni D; Gottardi E; Fava M; Messa F; Carturan S; Busca A; Guerrasio A; Saglio G
Blood; 2003 Jul; 102(2):773-4; author reply 774. PubMed ID: 12835231
[No Abstract] [Full Text] [Related]
8. Digital droplet PCR-based absolute quantification of pre-transplant NPM1 mutation burden predicts relapse in acute myeloid leukemia patients.
Bill M; Grimm J; Jentzsch M; Kloss L; Goldmann K; Schulz J; Beinicke S; Häntschel J; Cross M; Vucinic V; Pönisch W; Behre G; Franke GN; Lange T; Niederwieser D; Schwind S
Ann Hematol; 2018 Oct; 97(10):1757-1765. PubMed ID: 29785446
[TBL] [Abstract][Full Text] [Related]
9. Abnormal in vitro differentiation of clonogenic B-cells in common acute lymphoblastic leukemia in complete remission. A marker for minimal residual disease?
Bréard J; Mathé G; Consolini R
Suppl J Med Oncol Tumor Pharmacother; 1988; 1():47-50. PubMed ID: 2977810
[No Abstract] [Full Text] [Related]
10. Flow cytometric identification of intracellular antigens: detection of minimal residual leukemia.
Gore S; Kastan M; Civin C
Bone Marrow Transplant; 1990 Jul; 6 Suppl 1():39-41. PubMed ID: 1697192
[TBL] [Abstract][Full Text] [Related]
11. Autologous bone marrow transplantation in acute non lymphocytic leukemia.
Gorin NC
Rev Fr Transfus Immunohematol; 1985 Nov; 28(5):463-75. PubMed ID: 3912924
[No Abstract] [Full Text] [Related]
12. Cellular dynamics of leukemias.
Raza A; Preisler HD
Crit Rev Oncog; 1990; 1(4):373-88. PubMed ID: 2083288
[No Abstract] [Full Text] [Related]
13. Phenotypic heterogeneity in acute leukemia.
Ryan DH
Clin Chim Acta; 1992 Mar; 206(1-2):9-23. PubMed ID: 1572082
[No Abstract] [Full Text] [Related]
14. Detection of central nervous system involvement in patients with leukemia or non-Hodgkin's lymphoma by immunological marker analysis of cerebrospinal fluid cells.
Hooijkaas H; Adriaansen HJ; van Dongen JJ
Cancer Treat Res; 1988; 38():149-71. PubMed ID: 2908594
[No Abstract] [Full Text] [Related]
15. Immunologic approaches to the classification of lymphomas and lymphoid leukemias.
Foon KA; Gale RP; Todd RF
Cancer Treat Res; 1988; 38():1-30. PubMed ID: 2908593
[No Abstract] [Full Text] [Related]
16. Bone marrow trephine biopsies as a source of nucleic acids for molecular diagnosis of haematological neoplasms.
Fey MF; Theilkäs L; Tobler A
Br J Haematol; 1990 Feb; 74(2):229-31. PubMed ID: 2317459
[No Abstract] [Full Text] [Related]
17. Autologous transplantation of an immunomagnetic bead purged marrow in patients with relapsed acute lymphoblastic leukemia.
Körbling M; Knauf W; Funderud S; Kvalheim G; Hunstein W
Haematologica; 1991 Mar; 76 Suppl 1():29-36. PubMed ID: 1650742
[TBL] [Abstract][Full Text] [Related]
18. Limited value of FLT3 mRNA expression in the bone marrow for prognosis and monitoring of patients with acute myeloid leukemia.
Kainz B; Fonatsch C; Schwarzinger I; Sperr WR; Jäger U; Gaiger A
Haematologica; 2005 May; 90(5):695-6. PubMed ID: 15921390
[TBL] [Abstract][Full Text] [Related]
19. Purging leukemia remission marrows with alkyl-lysophospholipids, preclinical and clinical results.
Vogler WR; Olson AC; Berdel WE; Okamoto S; Glasser L
Prog Clin Biol Res; 1990; 333():1-18; discussion 19-20. PubMed ID: 2308973
[TBL] [Abstract][Full Text] [Related]
20. On the heterogeneity of minimal residual disease in acute leukemia.
Hagenbeek A; Martens AC
Bone Marrow Transplant; 1989 Jan; 4 Suppl 1():9-12. PubMed ID: 2713565
[No Abstract] [Full Text] [Related]
[Next] [New Search]
